Review: hepatotoxicity and EGFR inhibition.
Ramanarayanan
Jeyanthi
J
Stratton VA Medical Center, Albany, NY 12208, USA. Jeyanthi.ramanarayanan@va.gov
Krishnan
Ganapathy S
GS
D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology; D051544:Cytochrome P-450 CYP3A / Q000187:drug effects* / Q000378:metabolism; D003577:Cytochrome P-450 Enzyme System / Q000187:drug effects; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D000069347:Erlotinib Hydrochloride; D006801:Humans; D010190:Pancreatic Neoplasms / Q000188:drug therapy*; D047428:Protein Kinase Inhibitors / Q000009:adverse effects*; D011799:Quinazolines / Q000009:adverse effects*
D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D003577:Cytochrome P-450 Enzyme System; D000069347:Erlotinib Hydrochloride; D051544:Cytochrome P-450 CYP3A; C510163:CYP3A4 protein, human; D066246:ErbB Receptors